Biotechnology company CytoDyn (OTCQB: CYDY) this morning
announced that the company’s president and CEO Nader Pourhassan was interviewed
on Uptick Newswire’s “Stock Day” Podcast. Among other highlights, Pourhassan
discussed the company’s main product, a humanized monoclonal antibody, which
has demonstrated positive results in HIV patients in a human clinical trial.
The antibody has received fast-track designation with the FDA, with the
potential of approval in early 2019. In addition, Pourhassan discussed a letter
of intent and acquisition of a company with advanced cancer treatment and the
company’s newly-hired board member, Michael Klump.
To listen to the full interview, visit http://ibn.fm/4qSie
To view the full press release, visit http://ibn.fm/EsFNQ
About CytoDyn
CytoDyn, Inc. is a publicly traded biotechnology
company focused on the development of new therapies for combating infection
with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has
the potential to drive groundbreaking advancements in developing the next
generation of HIV treatments. The clinical-stage biotechnology company engages
in the clinical development and potential commercialization of humanized
monoclonal antibodies for the treatment and prevention of human
immunodeficiency virus infection. Its product pipeline includes PRO 140,
CytoFeline, and Cytolin. The company was founded by Allen D. Allen on
May 2, 2002 and is headquartered in Vancouver, WA. For more information,
visit the company’s website at www.Cytodyn.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment